La catena delle opzioni mostra i dati chiave delle opzioni azionarie di B2Gold a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per B2Gold..

B2Gold (AMEX:BTG) Azioni, Catena delle Opzioni

B2Gold

B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into various markets. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.

Gold.goldbar.goldnugget.shutterstock

News

Commodities

Movers

Trading Ideas

Market Vectors ETF Trust Market Vectors Gold Miners

GDXJ

GOLD

L&#39;oro supera i 3.000 dollari mentre la criptovaluta arranca: quale asset si conferma porto sicuro in tempi di incertezza economica?

Oro vs Bitcoin: chi sta vincendo la battaglia come miglior bene di rifugio?

B2Gold Corp

Bitcoin Gold - United States Dollar

STKd 100% Bitcoin & 100% Gold ETF

Bitcoin Group SE

BIGTINCAN HLDGS LTD by BIGTINCAN HLDGS LTD.

BITCOIN GENERATION INC by Bitcoin Generation Inc.

Bitcoin Generation Inc

BT Group PLC

BTS GRP HLDGS PUB CO by BTS Group Holdings Public Company Ltd

BTS Group Holdings PLC

BTS GRP HLDGS PUB NVDR by BTS Group Holdings Public Company Ltd

BTG PLC SP/ADR by BTG plc

VIAV

VIAVI Says It Advanced Railway Communication Modernization As Part Of MORANE-2 Project

<ul>
<li>Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210's favorable safety profile and general consistency with the Primary Study Phase in patients with CRS&nbsp;</li>
<li>In the CRS patient subgroup with nasal polyps, analysis showed improvements in both symptoms and polyp size in Sham group patients that received crossover LYR-210</li>
<li>Lyra continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025&nbsp; &nbsp;</li>
</ul>
&nbsp;<a href="https://www.globenewswire.com/Tracker?data=0nqUTmfTa7kAyoK1CpcXuNYLiJ6YAYAA8NlhjF0-efZbTT5_LRWyqiC9FEO4fu8Mo_PiDBhkVJSjonbc4QJbo3WXRXY_WpNVEJJ37reMm1w=">Lyra Therapeutics</a>, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>), ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS),&nbsp;today announced that the Company plans to present results from the 52-week Extension Stage of the ENLIGHTEN 1 Phase 3 study for LYR-210, the Company's lead product candidate for CRS, at the annual Combined Otolaryngology Spring Meetings (COSM 2025) being held May 14-18 in New Orleans.
The poster will present 52-week results from the Extension Stage of the ENLIGHTEN 1 study in patients with CRS, including the following highlights:
<ul>
<li>LYR-210 was generally well tolerated and no treatment-related serious adverse events reported through Week 52.</li>
<li>Repeat LYR-210 treatment demonstrated a favorable safety profile, similar to that observed in the Primary Study Stage in patients with CRS.</li>
<li>Durable symptom control through 52 weeks observed after LYR-210 treatment cessation (LYR-Sham group) in both non-polyp and polyp patients.</li>
<li>In non-polyp patients, despite showing a strong Sham effect in the Primary Study Stage, there was further meaningful improvement in symptoms in crossover patients that subsequently received LYR-210 in the Extension Stage.</li>
<li>In the CRS patient subgroup with nasal polyps, crossover Sham-LYR group improved in both symptoms and polyp size consistent with LYR-210 treatment in the Primary Study Stage. &nbsp;</li>
</ul>
The poster presentation on LYR-210 is planned to take place during these poster sessions at COSM 2025:
<ul>
<li>Poster Title:&nbsp;LYR-210 Sinonasal Corticosteroid Implants for Chronic Rhinosinusitis: 52-week outcomes from the Phase 3 ENLIGHTEN 1 trial &nbsp;</li>
<li>Location: Elite Exhibit Hall at the Hyatt Regency New Orleans &nbsp;</li>
<li>Date and Time:&nbsp;Poster Sessions, Fri., May 16&nbsp;at 9:00 a.m.-7:00 p.m. CT and Sat., May&nbsp;17 at 9:00 a.m.-4:00 p.m. CT</li>
</ul>
The ENLIGHTEN program consists of two pivotal Phase 3 clinical trials, ENLIGHTEN 1 and ENLIGHTEN 2, to evaluate the efficacy and safety of LYR-210 for the treatment of CRS. Each ENLIGHTEN trial enrolled approximately 180 CRS patients who have failed medical management and have not had prior ethmoid sinus surgery, randomized 2:1 to either LYR-210 (7500µg mometasone furoate) or sham control for 24 weeks.
About LYR-210 LYR-210 is an investigational product candidate for the treatment of chronic rhinosinusitis (CRS) in patients who have failed current therapies and require further intervention. LYR-210 is a bioabsorbable nasal implant designed to be inserted in a simple, in-office procedure. LYR-210 is intended to deliver six months of continuous anti-inflammatory therapy, mometasone furoate, to the sinonasal passages to treat CRS. LYR-210 is being evaluated in the ENLIGHTEN pivotal Phase 3 clinical program.

Biotech

General

LYRA

Lyra Therapeutics Announces It Will Present 52-Week Extension Stage Results For ENLIGHTEN 1 Phase 3 Study For LYR-210 For The Treatment of Chronic Rhinosinusitis At COSM May 14-18 2025 In New Orleans

Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) raises FY2025 sales outlook from $1.75 billion-$1.76 billion to $1.93 billion-$1.94 billion vs $1.93 billion estimate.

Guidance

Dayforce Raises FY2025 Sales Guidance From $1.75B-$1.76B To $1.93B-$1.94B vs $1.93B Est; Expects Q2 Sales Of $454M-$460M vs $465.53M Est

Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy had increased overall survival, progression free survival, and duration of response compared to patients treated with gemcitabine/nab-paclitaxel SoC -
- VCN-01 was well-tolerated, with transient and reversible adverse events (AEs), meeting primary safety endpoint -
- Greater differences between the treatment arms were observed in patients receiving 2 doses of VCN-01 -
- Data to be reviewed during a Key Opinion Leader webinar Featuring Dr. Manuel Hidalgo Medina and Dr. Mike Pishvaian on Wednesday May 7th, 2025 at 0800 US EDT -
ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Theriva&#x2122; Biologics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NYSE">TOVX</a>), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced positive topline outcomes from the VIRAGE Phase 2b clinical trial evaluating the Company's lead product candidate VCN-01 (zabilugene almadenorepvec) plus standard-of-care (SoC) chemotherapy gemcitabine/nab-paclitaxel as a first line therapy for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) for whom gemcitabine/nab-paclitaxel is the recommended first-line treatment option. VCN-01 is a systemically-administered, tumor selective, stroma-degrading oncolytic adenovirus that has been granted Orphan Drug Designation and Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.

TOVX

Theriva Biologics Reports Topline Findings From VIRAGE Phase 2b Trial Of VCN-01 In Pancreatic Cancer

CLMB

Climb Channel Solutions Says It Partnered With Smartsheet For Industry-Leading Collaborative Work Management

Dayforce (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DAY#TSX">DAY</a>) sees Q2 sales of $454.000 million-$460.000 million vs $464.44 million analyst estimate.

TSX:DAY

Dayforce Sees Q2 Sales $454.000M-$460.000M vs $464.44M Est

Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) sees Q2 sales of $60.000 million-$63.000 million vs $67.22 million analyst estimate.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Avadel Pharmaceuticals Sees Q2 Sales $60.000M-$63.000M vs $67.22M Est

Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) raises FY2025 sales outlook from $240.00 million-$260.00 million to $255.00 million-$265.00 million vs $330.28 million estimate.

Avadel Pharmaceuticals Raises FY2025 Sales Guidance from $240.00M-$260.00M to $255.00M-$265.00M vs $330.28M Est

Dayforce (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DAY#TSX">DAY</a>) sees FY2025 sales of $1.929 billion-$1.944 billion vs $1.93 billion analyst estimate.

Dayforce Sees FY2025 Sales $1.929B-$1.944B vs $1.93B Est

Earnings

PSBD

Palmer Square Capital BDC Q1 EPS $0.40 Misses $0.44 Estimate, Sales $31.21M Miss $32.55M Estimate

Full Year 2025 Interim Corporate Financial Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Guidance Issued May 7, 2025</td>
<td>Guidance Issued February 26, 2025</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>FY 2025 Revenue</td>
<td>$1.550 billion - $1.585 billion</td>
<td>$1.545 billion - $1.610 billion</td>
</tr>
<tr>
<td>FY 2025 Adjusted fully diluted EPS</td>
<td>$6.60 - $6.70</td>
<td>$7.00 - $7.20</td>
</tr>
</tbody>
</table>
</figure>

LNTH

Lantheus Lowers FY25 Outlook: Adj EPS From $7.00-$7.20 To $6.60-$6.70 Vs $7.08 Estimate; Sales From $1.54B-$1.61B To $1.55B-$1.58B vs $1.59B Estimate

Obsidian Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OBE#AMEX">OBE</a>) reported quarterly earnings of $0.14 per share. This is a 27.27 percent increase over earnings of $0.11 per share from the same period last year. The company reported $147.20 million in sales this quarter. This is a 21.71 percent increase over sales of $120.94 million the same period last year.

Obsidian Energy Q1 EPS $0.14 Up From $0.11 YoY, Sales $147.20M Up From $120.94M YoY

The next frontier in decentralized finance, according to RabbitX founder Ming Wu, lies in expanding perpetual futures trading beyond crypto into real-world assets, stocks and even interest rate derivatives.
In an interview with Benzinga, Wu outlined a vision for how the perpetuals landscape could evolve in the next few years—one centered on greater accessibility, more diverse asset classes and liquidity innovations.
"What excites me most is opening up perpetual trading to a broader range of assets. RWAs, commodities, interest rates and stocks," Wu said. "This unlocks completely new trading and hedging strategies that haven't been available to most DeFi users."
RabbitX, a decentralized derivatives exchange, is pushing toward synthetic exposure to traditional markets. 
Wu emphasized that this shift could reshape the market by lowering barriers to high-leverage trading in asset classes typically gated behind brokerage accounts and geographic restrictions. 
"Perpetual futures on equities like TSLA or indices like the S&amp;P 500 could democratize access to leverage for traders globally," he added.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45231848/bitcoin-eyes-100000-experts-assert-but-will-the-federal-reserve-play-ball">Bitcoin Eyes $100,000, Experts Assert, But Will The Federal Reserve Play Ball?</a>
One of RabbitX's more radical proposals is the tokenization of its Liquidity Pool Vault (RLP tokens), which Wu said could deepen market efficiency and create tradable secondary markets for liquidity itself. 
"By allowing LPs to tokenize and move their capital freely, we enable better capital allocation and collateral use in lending and borrowing protocols," he explained.
Wu also highlighted the firm's zero-fee model as a deliberate bet on shifting the economics of decentralized exchanges. 
Instead of charging traders directly, RabbitX earns from API and performance fees, an approach he hopes more platforms will adopt. 
"Fee-free trading shouldn&#8217;t be a marketing gimmick, it can be a sustainable part of a broader monetization strategy if designed properly," he said.
Despite regulatory uncertainty and technical complexity, Wu remains optimistic that perpetuals for traditional assets will gain traction, provided infrastructure such as robust oracles and liquid secondary markets keep pace.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45227730/bnb-price-to-surge-to-2775-by-2028-driven-by-bitcoin-and-ethereum-correlation-says-standard-chartered">BNB Price To Surge To $2,775 By 2028, Driven By Bitcoin And Ethereum Correlation, Says Standard Chartered</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

RabbitX Founder Eyes Real-World Assets And Liquidity Tokenization As The Future Of Perpetual Trading

Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.55 by 5.45 percent. This is a 34.88 percent increase over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $481.80 million which beat the analyst consensus estimate of $476.73 million by 1.06 percent. This is a 11.66 percent increase over sales of $431.50 million the same period last year.

Earnings Beats

Dayforce Q1 Adj. EPS $0.58 Beats $0.55 Estimate, Sales $481.80M Beat $476.73M Estimate

Leerink Partners analyst Marc Goodman upgrades Amylyx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) from Market Perform to Outperform and raises the price target from $4 to $10.

Upgrades

Price Target

Analyst Ratings

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Leerink Partners Upgrades Amylyx Pharmaceuticals to Outperform, Raises Price Target to $10

Delek Logistics Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKL#NYSE">DKL</a>) reported quarterly earnings of $0.73 per share which missed the analyst consensus estimate of $0.82 by 10.98 percent. This is unchanged from the same period last year. The company reported quarterly sales of $249.93 million which missed the analyst consensus estimate of $251.07 million by 0.45 percent. This is a 0.85 percent decrease over sales of $252.07 million the same period last year.

Earnings Misses

Delek Logistics Partners Q1 EPS $0.73 Misses $0.82 Estimate, Sales $249.93M Miss $251.07M Estimate

SRPT: -27% &#x7C; <a href="https://www.benzinga.com//node/45247524">Sarepta Therapeutics shares are trading lower after the company reported a Q1 adjusted EPS miss.</a>
&nbsp;
UBER: -7% &#x7C; <a href="https://www.benzinga.com//node/45248321">Uber shares are trading lower after the company reported Q1 revenue below estimates.</a>
&nbsp;
NCEW: 249% &#x7C; <a href="https://www.benzinga.com//node/45247972">New Century Logistics Signs Memorandum of Understanding With Soradynamics To Develop And Deploy An In-Vehicle Drone Logistics System</a>

NCEW

SRPT

UBER

Market-Moving News for May 7th

Advances Relationship and Collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education
<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4421174-1&amp;h=2098434031&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a>&nbsp;("Genprex" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnpx#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that following the recent completion of its two-year Sponsored Research Agreement (SRA) with the University of Pittsburgh of the Commonwealth System of Higher Education (Pitt) to study Type 1 diabetes (T1D) and Type 2 diabetes (T2D), the parties have entered into a new SRA to study GPX-002, the Company's gene therapy for diabetes, in T1D and T2D in animal models.

Penny Stocks

Contracts

GNPX

Genprex Enters Sponsored Research Agreement With The University Of Pittsburgh To Study Diabetes Gene Therapy In Type 1 And Type 2 Diabetes

Dayforce (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DAY#TSX">DAY</a>) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.54 by 7.41 percent. This is a 34.88 percent increase over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $481.80 million which beat the analyst consensus estimate of $477.01 million by 1.00 percent. This is a 11.66 percent increase over sales of $431.50 million the same period last year.

Dayforce Q1 Adj. EPS $0.58 Beats $0.54 Estimate, Sales $481.80M Beat $477.01M Estimate

New York Times Q1 Adj. EPS $0.41 Beats $0.34 Estimate, Sales $636.00M Beat $634.83M Estimate

Press Releases

B2Gold Announces Pricing of Upsized Offering of Convertible Senior Notes

B2Gold Completes Upsized Offering of Convertible Senior Notes

B2Gold Fourth Quarter and Full Year 2024 Financial Results – Conference Call Details

B2Gold Announces Positive Preliminary Economic Assessment Results for the Antelope Deposit at the Otjikoto Mine in Namibia; After-Tax NPV (5%) of $131 Million with an After-Tax IRR of 35%

B2Gold Reports Q4 and Full Year 2024 Results; Achieved 2024 Total Gold Production and Consolidated Cost Guidance; Goose Project Remains On Track for First Gold in Q2 2025 and Total Capital Estimate Remains at C$1,540 Million; Q1 2025 Dividend of US$0.02 per Share Declared

B2Gold Completes Phase 2 Expansion of Fekola Solar Plant in Mali

B2Gold Announces Updated Mineral Reserve Life of Mine Plan for the Goose Project; Commencing a Study to Expand Mill Throughput at the Goose Project; B2Gold Confirms Construction and Mine Development Cash Expenditure Estimate of C$1,540 million

Comments

B2Gold

B2Gold (BTG) Opzioni

B2Gold (AMEX:BTG) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO